Nvidia, AMD to pay 15% of China chip sales revenue to US govt- FT
Ludwig Enterprises, Inc. (OTC:LUDG) announced the appointment of Garth Lees-Rolfe as an independent director, effective Monday. The decision was made by the company’s board of directors and was disclosed in a press release statement based on a recent SEC filing.
According to the filing, Mr. Lees-Rolfe will serve as a director until the expiration of his term, the election and qualification of a successor, or until his earlier death, resignation, disqualification, or removal. The company stated there are no family relationships among any of its directors or executive officers.
Mr. Lees-Rolfe has over 19 years of experience in finance, accounting, and strategic financial planning. He is currently the Chief Financial Officer of ABLi Therapeutics, Inc., a private clinical-stage biotechnology company, a position he has held since April 2025. Prior to this role, he served as Chief Financial Officer of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) from April 2024 to April 2025 and as Vice President of Finance at the same company from November 2022 to April 2024. According to InvestingPro, IKT currently has a market capitalization of $124 million and maintains strong liquidity with a current ratio of 11.01. The company’s stock is currently trading near $1.66, with analysts setting an $8 price target.
Mr. Lees-Rolfe’s previous positions also include serving as Vice President, Finance for F-Star, Inc. (NASDAQ:FSTX) from December 2021 to November 2022. Earlier in his career, he spent 16 years in public practice, primarily with Ernst & Young, where he was most recently a Senior Manager from 2016 to 2021.
He holds a Bachelor of Business from the Queensland University of Technology and a Graduate Certificate in Applied Finance from Kaplan Professional. Mr. Lees-Rolfe is a licensed Certified Public Accountant in Massachusetts and a Chartered Accountant in Australia and New Zealand.
Ludwig Enterprises is incorporated in Nevada and operates in the medical laboratories sector. The company does not currently have securities registered on a national securities exchange.
This information is based on a press release statement and details provided in a recent SEC filing.
In other recent news, Inhibikase Therapeutics announced the appointment of David McIntyre as its new Chief Financial Officer. McIntyre brings over 20 years of experience in the life sciences sector, having held senior roles at companies like Anthos Therapeutics and HeartWare International. This leadership change comes as the company advances its lead product, IkT-001, for treating pulmonary arterial hypertension (PAH). The company is preparing for a Phase 2b ’702’ trial of IkT-001, following recent IND-clearance from the FDA. Inhibikase is also seeking Orphan Drug Designation for IkT-001Pro in the treatment of PAH.
H.C. Wainwright has maintained a Neutral rating on Inhibikase Therapeutics, reflecting the company’s ongoing progress with its drug candidate IkT-001Pro. The drug, a prodrug of imatinib, has already received FDA Orphan Drug Designation for another indication. The company is in discussions with the FDA to secure similar designation for PAH. Inhibikase has enhanced its manufacturing process for IkT-001Pro, which includes new dosage forms and a more efficient production process. These developments are part of the company’s efforts to differentiate IkT-001Pro from generic imatinib mesylate.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.